COLUMBIA, MD
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)FOUNDATION FIGHTING BLINDNESS RETINAL DEGENERATION FUND, founded in 2003, is a community nonprofit in the Medical Research sector that reported $8.8M in total revenue in fiscal year 2023. Revenue decreased 6% compared to the prior year. The organization ran a surplus of $7.4M, a strong 85% operating margin.
THE FOUNDATION FIGHTING BLINDNESS RETINAL DEGENERATION FUND'S MISSION IS TO ACCELERATE THE TRANSLATION OF RETINAL LABORATORY-BASED RESEARCH INTO CLINICAL TRIALS TO EXPEDITE THE COMMERCIALIZATION OF PATIENT THERAPIES.
THE THREE LARGEST PROGRAM SERVICES ACCOMPLISHMENTS (AS MEASURED BY INVESTMENT SIZE) FOR THE FOUNDATION FIGHTING BLINDNESS RETINAL DEGENERATION FUND (FFB-RDF) DURING FISCAL YEAR 2024 WERE EQUITY...
THE THREE LARGEST PROGRAM SERVICES ACCOMPLISHMENTS (AS MEASURED BY INVESTMENT SIZE) FOR THE FOUNDATION FIGHTING BLINDNESS RETINAL DEGENERATION FUND (FFB-RDF) DURING FISCAL YEAR 2024 WERE EQUITY INVESTMENTS IN OPUS GENETICS, OSANNI BIO, AND ATSENA THERAPEUTICS. OPUS GENETICS, ATSENA THERAPEUTICS AND OSANNI BIO ARE ALL CLINICALLY STAGED THERAPY COMPANIES. EACH OF THESE COMPANIES IS FOCUSED ON ADVANCING PROMISING THERAPIES FOR RETINAL DEGENERATIVE DISEASES.FISCAL 2024 SUMMARY:FFB-RDF INVESTED AN ADDITIONAL $1,449,835 IN OPUS GENETICS TO HELP ADVANCE ITS PIPELINE OF ORPHAN INHERITED RETINAL DISEASE GENE THERAPY INDICATIONS INCLUDING LCA5, BEST1, RHO, RDH12 AND MERTK. THE FIRST PATIENT WAS DOSED IN THE LCA5 PHASE I/II CLINICAL TRIAL IN AUGUST 2023. FFB-RDF INVESTED $2,807,443 IN ATSENA THERAPEUTICS TO SUPPORT THE ADVANCEMENT OF TWO CLINICALLY STAGED GENE THERAPY ASSETS FOR LCA1 AND XLRS, AND THE PRECLINICAL DEVELOPMENT OF GENE THERAPY ASSETS TOWARDS USH1B AND STARGARDT'S DISEASE. FFB-RDF INVESTED $3,000,000 IN OSANNI BIO TO SUPPORT THE ADVANCEMENT OF TWO CLINICALLY STAGED ASSETS AIMED AT REDUCING DRUSEN IN DRY AGE-RELATED MACULAR DEGENERATION AND GEOGRAPHIC ATROPHY.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2023 | 2022 | Change | |
|---|---|---|---|
| Revenue | $8,751,135 | $9,316,837 | -0.1% |
| Expenses | $1,309,685 | $1,014,874 | +0.3% |
| Net Income | $7,441,450 | $8,301,963 | -0.1% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| MARK BLUMENKRANZ MD MMS | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| DAVID BRINT | EX OFFICIO DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| WARREN THALER | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| JOSE-ALAIN SAHEL MD | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $15,000 |
| ADRIENNE GRAVES PHD | CHAIRMAN | 1.00 |
Director
|
$0 | $0 | $0 |
| KELLY LISBAKKEN | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| JACQUE DUNCAN MD | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $75,000 |
| JONATHAN STEINBERG MD | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| TONY ADAMIS MD | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| JEAN BENNETT MD PHD | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| CATHERINE BOWES RICKMAN PHD | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $15,000 |
| JASON D MENZO | CEO | 8.00 |
Officer
|
$104,122 | $68,385 | $588,996 |
| RUSSELL W KELLEY | MANAGING DIRECTOR, RD FUND | 40.00 |
Officer
|
$347,534 | $64,959 | $412,493 |
| PETER GINSBERG | COO | 8.00 |
Officer
|
$72,505 | $63,272 | $425,796 |
| ALICIA KEMBLE | SENIOR VENTURE ASSOCIATE | 40.00 |
Highest
|
$135,548 | $21,753 | $157,301 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2025 | No data | No data | No data | No data |
| 2024 | $8,751,135 | $1,309,685 | $52,460,807 | $7,441,450 |
| 2023 | $9,316,837 | $1,014,874 | $47,303,067 | $8,301,963 |
| 2022 | $15,424,974 | $1,051,912 | $45,350,093 | $14,373,062 |
| 2022 | $15,424,974 | $1,051,912 | $45,350,093 | $14,373,062 |
| 2021 | $21,228,882 | $2,021,967 | $31,011,511 | $19,206,915 |
| 2020 | $11,939,089 | $2,984,402 | $11,438,657 | $8,954,687 |
Compare FOUNDATION FIGHTING BLINDNESS RETINAL DEGENERATION FUND with other nonprofits in Maryland and across the country.